Lakings D B, Friis J M, Lunan C M, VanderLugt J T, Mohrland J S
Drug Metabolism Research, Upjohn Company, Kalamazoo, Michigan 49001.
Pharm Res. 1989 Jan;6(1):53-7. doi: 10.1023/a:1015899602741.
Furegrelate sodium is a thromboxane synthetase inhibitor with potential for the treatment of various diseases including hypertension, thrombosis, and renal disorders. The absorption and disposition of the parent drug in normal male volunteers have been studied after single- and multiple-dose oral administration. The results from the single-dose study indicate that furegrelate is rapidly absorbed, with a Tmax of 1.0-1.7 hr, has an apparent terminal disposition rate constant of 0.12-0.17 hr-1, and is eliminated primarily by the kidney, with 62-78% of the dose excreted as parent drug. After multiple-dose oral administration for 4.5 days using a b.i.d. dosing regimen, no apparent change in the absorption, disposition, and elimination kinetics is detected and only a slight potential for drug accumulation is observed.
呋格雷酯钠是一种血栓素合成酶抑制剂,具有治疗多种疾病的潜力,包括高血压、血栓形成和肾脏疾病。在正常男性志愿者中,已对单次和多次口服给药后母体药物的吸收和处置情况进行了研究。单剂量研究结果表明,呋格雷酯吸收迅速,达峰时间为1.0 - 1.7小时,表观终末处置速率常数为0.12 - 0.17小时⁻¹,主要经肾脏消除,62% - 78%的剂量以母体药物形式排泄。采用每日两次给药方案多次口服给药4.5天后,未检测到吸收、处置和消除动力学有明显变化,仅观察到轻微的药物蓄积可能性。